Abstract
Benign prostate hyperplasia (BPH) is the most common proliferative disorder affecting older men and results in prostate enlargement and lowered urinary tract symptoms. Jaeumganghwa-tang (JGT), an oriental traditional herbal formula, has been used in China (Zi-yin-jiang-huo-tang in Chinese), Japan (Jiin-koka-to in Japanese), and Korea for many years. Effects of JGT on prostate dihydrotestosterone (DHT) level and prostatic hyperplasia were investigated using a rat model, in which BPH was induced using testosterone propionate (TP). Rats were divided into five groups. One group was used as a normal, and four groups received subcutaneous injections of TP for 4 weeks to induce BPH. JGT (200 or 400 mg/kg) was administered daily for 4 weeks by oral gavage concurrently with TP injections, and rats were sacrificed at scheduled times. Prostates were weighed, and histopathologic examination was conducted. DHT levels in serum and the prostate were measured, and the expression of proliferating cell nuclear antigen (PCNA) protein was investigated using Western blotting. BPH animals showed increases in absolute and relative weights of the prostate, levels of DHT in serum and the prostate, and expression of PCNA in the prostate, whereas JGTtreated animals showed significant reductions in these indices compared with the BPH animals. Administration of JGT attenuated TP-induced epithelial hyperplasia. These findings indicate that JGT inhibits the development of BPH, an effect closely associated with a reduction in DHT level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. (2004) Dihydrotestosterone and the prostate: The scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172, 1399–1403.
Arruzazabala ML, Mas R, Molina V, Noa M, Carbajal D, and Mendoza N (2006) Effect of D-004, a lipid extract from the Cuban royal palm fruit, on atypical prostate hyperplasia induced by phynylephrine in rats. Drug R D 7, 233–241.
Arruzazabala ML, Molina V, Mas R, Carbajal D, Marrero D, Gonzalez V et al. (2007) Effects of coconut oil on testosterone-induced prostatic hyperplasia in Sprague-Dawley rats. J Pharm Pharmacol 59, 995–999.
Bhargava S, Canda AE, and Chapple CR (2004) A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol 14, 2–6.
Black L, Naslund MJ, Gilbert Jr TD, Davis EA, and Ollendorf DA (2006) An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Managed Care 12, 99–110.
Bullock TL and Andriole GL (2006) Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs 11, 111–123.
Carson C and Rittmaster R (2003) The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2–7.
Dunnett CW (1964) New tables for multiple comparisons with control. Biometrics 20, 482–491.
Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R et al. (2005) Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol 25, 9350–9359.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 324, 1185–1191.
Hutchison A, Farmer R, Verhamme K, Berges R, and Navarrete R (2007) The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51, 207–215.
Huynh H (2002) Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 20, 1297–1303.
Jung D, Ha H, Lee HY, Lee JA, Lee JK, Huang DS et al. (2010) Stimulation of the immune response by Yin-Tonifying formula. J Korean Orien Med 31, 112–123.
Kang TH, Bang JY, Kim MH, Kang IC, Kim HM, and Jeong HJ (2011) Atactylenolide III, a sesquiterpenoid, induces apoptosis in human lung carcinoma A549 cells via mitochrondria-mediated death pathway. Food Chem Toxicol 49, 514–519.
Kil JS, Kim MG, Choi HM, Lim JP, Boo Y, Kim EH et al. (2008) In hibitory effects of Angelicae Gigantis Radix on osteoclast formation. Phytother Res 22, 472–476.
Kim YK, Kim HJ, Kim WS, Park HJ, Moon G, Kim DW et al. (2004) Inhibitory effect of Jaeumganhwa-tang on allergic inflammatory reaction. Korean J Orien Inter Med 25, 174–182.
Lai JS, Xia Q, Zhang XB, Zhao GP, Xu SL, and Zheng DS (2004) Expression and significance of PCNA and p27 in benign prostatic hypertrophy and prostate carcinoma. Zhonghua Zhong Liu Za Zhi 26, 476–478.
Li SH, Ryu JH, Park SE, Cho YS, Park JW, Lee WJ et al. (2010) Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha. J Nutr Biochem 21, 801–808.
Park YK, Chung YS, Kim YS, Kwon OY, and Joh TH (2007) Inhibition of gene expression and production of iNOS and TNF-alpha in LPSstimulated microglia by methanol extract of Phellodendri cortex. Int Immunopharmacol 7, 955–962.
Preuss HG and Adderly B (1998) In The Prostate Cure. pp. 1–251. Crown Publishier, Inc., New York, NY.
Roehrborn CG, Nuckolls JG, Wei JT, Steers W, and BPH Registry and Patient Survey Steering Committee (2007) The benign prostatic hyperplasia registry and patient survey: Study design, methods and patient baseline characteristics. BJU Int 100, 813–819.
Roehrborn CG and Rosen RC (2008) Medical therapy options for aging men with benign prostatic hyperplasia: Focus on alfusozin 10 mg once daily. Clin Interv Aging 3, 511–524.
Roehrborn CG, Bruskewitz R, Nickel J, McConnell J, Saltzman B, Gittelman M et al. (2004) Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171, 1194–1198.
Shivji KK, Kenny MK, and Wood RD (1992) Proliferating cell nuclear antigen is required for DNA excision repair. Cell 69, 367–374.
Sun GP, Wan X, Xu SP, Wang H, Liu SH, and Wang ZG (2008) Antiproliferation and apoptosis induction of paeonal in human esophageal cancer cell lines. Dis Esophagus 21, 723–729.
Suzuki K, Okazaki H, Ono Y, Kurokawa K, Suzuki T, Onuma E et al. (1998) Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. Protstate 37, 70–76.
Veeresh Babu SV, Veeresh B, Patill AA, and Warke YB (2010) Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Eur J Pharmacol 625, 262–265.
Wiboonpun N, Phuwapraisirisan P, and Tip-pyang S (2004) Identification of antioxidant compound from Asparagus racemosus. Phytother Res 18, 771–773.
Yamashita A, Hayashi N, Sugimura Y, Cunha GR, and Kawamura J (1996) Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormaonereleasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate. Prostate 29, 1–14.
Yokozawa T, Cho EJ, Rhyu DY, Shibahara N, and Aoyagi K (2005) Glycyrrhizae Radix attenuated peroxynitrite-induced renal oxidative damage inhibition of protein nitration. Free Radic Res 39, 203–11.
Zhong W, Peng J, He H, Wu D, Han Z, Bi X et al. (2008) Ki67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 31, 8–15.
Author information
Authors and Affiliations
Corresponding author
Additional information
I. S. Shin and M. Y. Lee contributed equally.
Rights and permissions
About this article
Cite this article
Shin, I.S., Lee, M.Y., Lim, H.S. et al. Jaeumganghwa-tang, a traditional herbal formula inhibits the development of benign prostatic hyperplasia in rats. J Korean Soc Appl Biol Chem 55, 205–212 (2012). https://doi.org/10.1007/s13765-012-1174-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13765-012-1174-x